Objective: Patients who receive prolonged mechanical ventilation have high resource utilization and relatively poor outcomes, especially the elderly, and are increasing in number. The economic implications of prolonged mechanical ventilation provision, however, are uncertain and would be helpful to providers and policymakers. Therefore, we aimed to determine the lifetime societal value of prolonged mechanical ventilation. Design and Patients: Adopting the perspective of a healthcare payor, we developed a Markov model to determine the cost effectiveness of providing mechanical ventilation for at least 21 days to a 65-yr-old critically ill base-case patient compared with the provision of comfort care resulting in withdrawal of ventilation. Input data were derived from the medical literature, Medicare, and a recent large cohort study of ventilated patients. Measurements and Main Results: We determined lifetime costs and survival, quality-adjusted life expectancy, and cost effectiveness as reflected by costs per quality-adjusted life-year gained. Providing prolonged mechanical ventilation to the base-case pa-tient cost $55,460 per life-year gained and $82,411 per qualityadjusted life-year gained compared with withdrawal of ventilation. Cost-effectiveness ratios were most sensitive to variation in age, hospital costs, and probability of readmission, although less sensitive to postacute care-facility costs. Specifically, incremental costs per quality-adjusted life-year gained by prolonged mechanical ventilation provision exceeded $100,000 with age >68 and when predicted 1-yr mortality was >50%. Conclusions: The cost effectiveness of prolonged mechanical ventilation provision varies dramatically based on age and likelihood of poor short-and long-term outcomes. Identifying patients likely to have unfavorable outcomes, lowering intensity of care for appropriate patients, and reducing costly readmissions should be future priorities in improving the value of prolonged mechanical ventilation. (Crit Care Med 2007; 35:1918-1927) KEY WORDS: cost-benefit analysis; respiration; artificial; tracheostomy; health services research; outcome and process assessment (health care)
M ore than 1 million persons admitted to U.S. intensive care units (ICUs) receive mechanical ventilation annually, although usually for just a few days (1) . However, nearly 10% of all critically ill patients and up to 34% of those ventilated for Ͼ2 days require extended periods of ventilatory support (2) (3) (4) . Prolonged mechanical ventilation (PMV) is most commonly defined by either Ն21 days of ventilation or Ն4 days of ventilation with placement of a tracheostomy (5) . Presently, there are Ͼ100,000 new PMV patients annually in the United States, half of whom are Medicare beneficiaries, although the PMV occurrence rate is increasing more rapidly than that for mechanical ventilation itself (6, 7) .
Unfortunately, PMV patients' care is expensive and their overall outcomes often poor (3, 8) . In 2005, Medicare-eligible PMV patients ranked third in summative inpatient charges by diagnostic group and first in charges per patient-significantly greater than the resource utilization of persons with sepsis, myocardial infarctions, or gastrointestinal bleeding (7) . These annual expenditures exceeding $20 billion do not include payments for extended stays in the long-term acute care, rehabilitation, and skilled nursing facilities to which Ͼ80% of PMV patients are discharged (2) . Despite receiving such a high level of care, Ͻ50% of PMV hospital survivors survive Ͼ1 yr (2, 9, 10) . Those who do survive often suffer significant disability in performing basic daily functions, experience reduced quality of life, and possess significant long-term caregiving needs (2, 8) .
Persons of age 65 yrs and older presently account for more than half of all ICU days in the United States (11) . However, this age group, whose members also have the highest baseline risk of respiratory failure and subsequent PMV, is expected to double in size between 2000 and 2030 and trigger a critical care workforce shortage in the process (6, 12) .
In light of the dramatic financial pressures associated with health care costs confronting U.S. society, cost-effectiveness analyses can be particularly valuable tools that enable providers, payors, and policymakers to better understand how to prioritize and target potential interventions within the process of care, optimize resource utilization, and plan for future changes (13) . There have been recent calls within the critical care field for greater attention to economic analyses of critical care from both clinicians and policymakers (14, 15) . Despite the high costs of PMV and often poor outcomes, there have been no formal economic analyses of PMV provision that incorporate either a lifetime time horizon or the contributions of acute as well as postacute care costs. To address these needs, we analyzed the economic impact of PMV provision.
MATERIALS AND METHODS

Study Design
We used decision analysis to compare the lifetime costs and survival of patients who received PMV (mechanical ventilation for Ն21 days with placement of a tracheostomy) with those who received comfort measures only resulting in withdrawal of ventilation (Table  1) . Clinical relevance guided the framing of our analyses, because we assumed that final decision making regarding mechanical ventilation continuation or withdrawal would be conducted during ventilator days 7 to 21. This 2-wk decision-making period allowed separation from analyses of those with very severe illness (and thus early death) and approximates similar decision strategies performed among the severely ill (16) . Although this strategy reflects a hypothetical situation and does not address patients' preferences for PMV from the time of ICU admission, we believe that it best approximates the experience of physicians, critically ill patients, and families in this situation. We felt that this design also realistically compared the value of PMV to its most intuitive alternative, i.e., withdrawal of ventilation based on either patients' or their families' preferences.
We followed recommendations for the conduct of cost-effectiveness analyses, incorporating a societal perspective (that of the perfect healthcare payor, i.e., a payor source that would reimburse costs uniformly and without exclusion for all relevant societal members), a lifetime time horizon, and a 3% annual discount rate (17) . All costs were adjusted to 2005 U.S. dollars using the medical component of the Consumer Price Index (18) .
Wherever possible, we based the clinical and economic inputs included in our model on what we felt were the most relevant, highest quality published studies ( Table 2 ). When we felt that the literature was unclear, particularly with regard to the clinical characteris-tics and costs of those who had mechanical ventilation withdrawn, we informed our estimates with data from an observational cohort study of 817 persons who received mechanical ventilation for Ն48 hrs at the University of Pittsburgh Medical Center and who subsequently had survival, functional status, and quality of life assessed at baseline as well as 3, 6, and 12 months from the time of intubation (41) . Because of the quality of its systematic screening process, the richness of data captured, and cohort size, the Pittsburgh data set primarily was used to inform estimates of hospital survival and discharge disposition, as well as the characteristics and costs of those who had ventilation withdrawn for comfort measures as described elsewhere (3) .
We used TreeAge Pro 2006 (TreeAge Software, Williamstown, MA) and Stata 9 (Stata, College Station, TX) in our analyses. The Duke University Institutional Review Board exempted our research from formal review.
Patient Population
Base-Case Patient. The base-case patient was a 65-yr-old, critically ill recipient of PMV who was a composite of genders and ethnic background. This reflects the average PMV patient age reported in other studies and ensures Medicare eligibility (2) . All base-case PMV patients were assumed to have been ventilated for Ն21 days and to have had a tracheostomy placed. Although 22% of those ventilated for Ն21 days in the Pittsburgh data set did not undergo tracheostomy placement, they did not have either statistically different mortality or costs than those with tracheostomies. We did not distinguish between medical and surgical patients, as others have found previously that there was no significant difference in adjusted 1-yr survival in this age group based on these groupings (41) .
Comparison Patient. The comparison group included those patients from whom ventilation was withdrawn without placement of a tracheostomy between ventilator days 7 and 21. Because the effect of ventilator withdrawal was assumed to be early death, severity of illness and other clinical factors-although part of the decision-making process-were less relevant to the model than the decision to withdraw ventilation itself in anticipation of death based on patients' or their families' wishes. For the patients in the withdrawal of ventilation group based on the Pittsburgh cohort, the median duration of care included 12 ventilator days (interquartile range, 10, 15), 13 ICU days (11, 16) , and 16 hospital days (12, 41) . Their median ICU day 1 acute physiology score was 60 (range, 42-78) and they had an average of three limitations in basic instrumental activities of daily living. There was variation in length of stay among patients in the Pittsburgh data set from whom ventilation was withdrawn. However, this variation served primarily to inform adjustments in reimbursement based on hospital length of stay outliers status, because overall group costs were based on Medicare's diagnosis related group code 475 (acute respiratory failure), as described below.
Process of Care Characteristics and Clinical Input Values
We attempted to examine a realistic trajectory of acute, postacute, and chronic facilitybased care that a PMV recipient might experience. In our model, a hospital survivor could be discharged either to home or a postacute care facility (long-term acute care [LTAC], skilled nursing, inpatient rehabilitation, or nursing home) (Figs. 1, 2; Table 2 ). If residing at home, a patient either remained healthy, experienced complications resulting in hospital readmission, or died. Persons discharged to postacute care facilities could be discharged home subsequently, experience complications resulting in hospital readmission, or be transferred to another postacute care facility. Additionally, skilled nursing facility discharges could move to a long-term nursing home or a nursing home with expertise in long-term ventilator management for those unable to be completely weaned from ventilation.
Clinical Effects
Incremental cost effectiveness of PMV was determined by using a Markov model in which outcomes during continuous cycles of 1 wk were calculated until no survivors remained (42) . We expressed our results in terms of costs, life-years, and incremental costeffectiveness ratios. Incremental cost-effectiveness ratios represent the ratio of incremental costs (costs of strategy 1 vs. costs of strategy 2) to incremental effects (life-years of strategy 1 vs. life-years of strategy 2). Because we adjusted life-years for quality of life as quantified in the form of utilities, incremental cost-effectiveness ratios are reported as costs per quality-adjusted life-year (QALY). Utilities are global quality-of-life measures particularly appropriate for analyses that take a societal perspective and can range from 0 (death) to 1 (ideal health). We used the declining exponential approximation of life expectancy method to build survival curves based on life expectancy predicted from U.S. life tables (43, 44) . This method generates a constant mortality rate over time predicted by the equation s ϭ e Ϫrt (s ϭ lifetime survival, r ϭ constant mortality rate, t ϭ time in years). We estimated that the base-case patient's life expectancy would be reduced by an amount (25%) similar to the observed 1-yr mortality observed for PMV patients discharged directly to home in the Pittsburgh cohort (3) . Therefore, the average PMV patient would have a life expectancy of 13.7 yrs-25% less than the 18.2 yrs expected of a typical 65-yr-old composite of gender, ethnicity, and race (44) . Such life expectancy corrections have been used in past cost-effectiveness analyses addressing the critically ill and are borne out by observational studies of survivors of sepsis and mechanical ventilation (33, 45) .
Costs
We incorporated in the model only direct costs attributable to patient care, excluding indirect costs such as hospital overhead, days lost from work, and others ( Table 2) . No additional costs were included for death occurring during hospitalization. Although we incorporated age-specific annual future expected health costs based on both Medicare and Blue Cross & Blue Shield data sets, we did not assume extra outpatient visits would be required in the months following hospital discharge (38) .
Because base-case patients were assumed to be 65 yrs of age, acute and postacute care costs were based on diagnosis-specific weightings and adjusted by length of stay data derived from the Pittsburgh cohort (3, 31, 46) . Briefly, Medicare's inpatient prospective payment system provides reimbursement by multiplying a standardized base payment by one of 526 condition-specific relative weights called diagnosis related groups (DRGs). This amount is then adjusted by a local wage index, a credit for medical education, and a hospital's provision for volume of care to poor patients (46) . For patients with especially short or long stays, there are additional algorithms for calculating additional "outlier" payments. Similar reimbursement procedures are followed for most facility-based postacute care. Our cost calculations are described in detail in the Appendix.
Sensitivity and Stratified Analyses
We performed one-way and multiway probabilistic (Monte Carlo) sensitivity analyses to explore the effect that our estimates' uncertainty had on costs and effectiveness. Ranges for clinical variables included in the sensitivity 
analyses were based on the most representative data available ( Table 2 ). In one-way sensitivity analyses, individual data inputs were varied across defined ranges to understand the importance of each to the overall model. Monte Carlo analyses allowed us to vary simultaneously all input data values in the model based on specific distributions over 1,000 simulations (42) . We assigned uniform distributions for costs and utilities and used beta distributions (shape defined by number of persons at risk for an event and the number not at risk, minimal value ϭ 0 and maximal value ϭ 1) for probabilities. The results of Monte Carlo analyses were quantified by the proportion of the simulations that showed incremental cost-effectiveness ratios Ͻ$100,000 per QALY. We also performed stratified analyses to explore areas of particular clinical interest including age, probability of 1-yr survival, and postacute care discharge disposition.
(a) Age. We performed separate analyses by age (18, 45, 55, 65, 70, 75 , 80, and 85) for the base-case PMV patient who received mechanical ventilation for Ն21 days. For these analyses, we used the Pittsburgh cohort, published data, and U.S. life tables to adjust by age group input variables including hospital mortality, costs, discharge location (home, LTAC, skilled nursing, or inpatient rehabilitation), and readmission rates (3, 30, 44) . (b) Probability of death at 1 yr. We built a logistic regression model using the Pittsburgh data set to stratify patients' risk of 1-yr death as high (Ն50% probability) or low (Ͻ50%) based on specific clinical variables. The final model included age and preadmission number of limitations in instrumental activities of daily living, while day-1 acute physiology score, gender, ethnicity, admission source, admitting service, admission diagnostic category, and preadmission activities of daily living limitations did not contribute significantly to the model. This model is similar to that described previously (41) . Costs and survival of the base-case PMV patients in the original cohort were then calculated as described above and added to the model. (c) Discharge disposition. We examined the effect that routine early hospital discharge to an LTAC had on cost-effectiveness ratios by modeling both a 14-day and 21-day hospital stay for cohorts of 1,000 PMV patients who all were sent to LTACs if they survived the hospitalization. We assumed that the summative duration of hospital plus LTAC care did not change overall. We reduced hospital mortality rates to 20% and increased LTAC mortality rates to 35% to account for the expected shift in mortality from one care location to the other. We also increased the probability of readmission from LTAC to hospital to 36% and 40% for 21-and 14-day hospital stays, respectively.
Finally, for purposes of contextual framing, we also performed analyses comparing ventilation withdrawal and both a) a patient characterized by an alternative PMV definition used by Medicare (DRGs 541 and 542 [receipt of mechanical ventilation for Ն4 days with tracheostomy placement for reasons other than a head, neck, or throat diagnosis with or without an operative procedure], previously known as DRG 483) as well as b) a patient ventilated short-term for an average length of time based on epidemiologic studies (ventilated Ն2 days but Յ7 days) ( 
RESULTS
Providing mechanical ventilation for 21 or more days to the 65-yr-old basecase patient gained 2.593 life-yrs or 1.745 QALYs at a cost of $143,808 compared with ventilation withdrawal. Therefore, the incremental costs of PMV were $55,460 per life-year and $82,411 per QALY gained (Table 3) .
One-way sensitivity analyses showed that incremental cost-effectiveness ratios were most sensitive to variance in acute hospitalization costs and readmission rate, aside from changes in costs of the comparison group (Fig. 3) . PMV was associated with costs of nearly $100,000 per QALY when hospitalization costs were maximized to $152,709 (base-case value $120,370) and slightly Ͼ$70,000 per QALY using the lower cost estimate of $83,411. Increasing the probability of first yr readmission to 65% (base case, 50%) increased the cost per QALY to $90,000, while reducing the rate to 30% 
LTAC, long-term acute-care facility; SNF, skilled-nursing facility; ICU, intensive care unit; OR, odds ratio; PMV, prolonged mechanical ventilation (mechanical ventilation Ն21 days). a Value used for PMV patients defined by ventilation Ն4 days plus placement of tracheostomy (diagnosisrelated group, 541/542) used in analyses was 23% (range, 17-50%) (2, 3) . Value for short-term (Ն2 days and Ͻ7 days) ventilation patients was 36% (range, 31-44%) (3, 39) ; b for short-term ventilation patients, values were home 15% (range, 7-33%), from SNF 23% (range, 10 -43%), from LTAC 29% (range, 25-35%), and from inpatient-rehabilitation facility 12% (range, 10 -38%) (3, 20 -22, 27) ; c value for first post-discharge year (for the following 3 yrs, this rate was successively halved); d derived from original Pittsburgh cohort using the methods of Drs. Brazier and Roberts (40) ; e hospital costs for PMV patients defined by ventilation Ն4 days plus placement of tracheostomy (diagnosis-related group, 541/542) were $111,194 (range, $83,411-$132,211) (3, 5) . Hospital costs for short-term-ventilation patients were $45,818 (range, $21,575-$68,046) (3, 5); f for short-term ventilation patients, costs for LTAC care were $52,817 (range, $49,120 -$56,514) and SNF care were $4,319 (range, $3,239 -$5,398) (20) . resulted in costs per QALY of $73,000. Varying age-related lifetime expected health costs had a more moderate effect on cost-effectiveness ratios. Interestingly, variation in postacute care facility-based mortality and costs had a relatively minor effect on cost-effectiveness ratios. Considering the uncertainty across all data inputs in the model simultaneously, Monte Carlo probabilistic analyses demonstrated that there was a 75% probability that the incremental costs per QALY gained by providing PMV care to the basecase patient compared with ventilation withdrawal were Ͻ$100,000.
The effect of patient age on incremental cost-effectiveness ratios was the most profound of any input variable tested, as shown in Figure 4 . PMV provision to 18yr-olds was associated with incremental costs of $14,289 per QALY gained compared with $127,859 for a 75-yr-old and Ͼ$206,000 for an 85-yr-old. Incremental costs per QALY gained with PMV provision exceeded $100,000 at age 68.
We found that there were wide differences in costs per QALY based on probability of 1-yr mortality. Table 4 shows that compared with ventilation withdrawal, it cost $60,967 per QALY gained to provide PMV to the base-case 65-yr-old with a Ͻ50% probability of 1-yr mortality, while it cost $101,787 to do the same for a more severely ill patient with a Ն50% likelihood of death by 1 yr. This difference was primarily related to improved survival rather than reduced costs in the group with a better prognosis.
Considering only persons discharged to LTACs, routine early transfer to an LTAC on ICU day 14 was associated with a reduction in average costs per QALY of Ͼ$46,000 ($94,558 per QALY vs. $141,608 per QALY) without adjustment for possible increases in LTAC mortality and hospital readmission rates. However, given a lower hospital mortality (20%) and a higher probability of LTAC death (30%), hospital readmissions from LTACs would need to be kept below 50% for cost savings to be realized with the early transfer strategy compared with the basecase LTAC strategy.
Finally, when we defined PMV using Medicare terminology (mechanical ventilation Ն4 days plus tracheostomy placement, DRG 483), the incremental costs of $73,629 per QALY were found to be very similar to those of the base-case patient. PMV costs by either definition were significantly greater than the $28,517 per QALY gained by care of a patient who required Ն2 but Ͻ7 days of ventilation.
DISCUSSION
We found that providing PMV is expensive for the base-case 65-yr-old pa-tient, although within the upper limits of conventional acceptability based on costs of $82,411 per QALY compared with withdrawal of ventilation in anticipation of death. However, the societal value of PMV provision becomes significantly less as patient age approaches the late 60s and the likelihood of short-term death increases beyond 50%. Although postacute care resource utilization is an increasing concern for the critically ill, the incremental cost effectiveness of PMV provision was much less sensitive to these costs than factors including patient age, costs of acute hospital care, and readmission rates.
Implications. Our findings are noteworthy because the elderly, who presently account for more than half of all ICU days and who had the highest lifetime incremental costs per QALY, are disproportionately affected by PMV (2) . Further, the number of elderly persons will grow significantly in the coming decades, potentially outpacing the supply of critical care physicians and drastically expanding Medicare costs (12, 32) . Therefore, our finding that the provision of an intervention that is steadily increasing in occurrence rate yet associated with both exceedingly high costs and poor outcomes among the expanding numbers of the very old highlights the potential future burden of chronic critical illness for which society should now plan. Maximizing the societal value of PMV will require both the development of interventions designed to improve PMV patients' health outcomes and reduce resource utilization, as well as thoughtful consideration of the appropriateness of prolonged ventilation provision in high-risk patients.
Our analyses are helpful in generating hypotheses about and directing the timing of PMV process of care changes. We found that an intervention that produced as minimal as a 10% improvement in utility reflecting quality of life has a noticeable affect on cost-effectiveness ra-tios. Potentially valuable resources for PMV survivors might include ICU follow-up clinics, rehabilitation programs, and disease management programs (5, 26, 47) . However, because of high early mortality and resource utilization, the potential impact of any PMV-specific interventions appears to be greatest when focused on acute care venues. Wider development of respiratory care units with lower nurse-to-patient ratios than found in intensive care units is one example of how acute hospitalization costs can be decreased, especially for hospitals without access to LTACs (48) . Earlier transfer of PMV patients from intensive care units to lower cost postacute care facilities such as LTACs may not reduce overall costs. Such a policy may only shift the burden of unstable acute and chronic critical illness to another care location ill equipped to handle it, resulting in either higher LTAC mortality or more readmissions to acute hospitals (10) . However, we were unable to determine the potential societal benefit associated with the gain of unfilled ICU beds that might be achieved with early LTAC transfer-an issue of growing relevance to the healthcare system given the increase in critically ill patients expected in the coming decades. Although there is a variety of postacute care venues that participate in PMV care-such as LTACs, skilled nursing facilities, rehabilitation facilities, and others-it is unknown if care in any one type is associated with better outcomes. At present, long-term care hospitals appear to vary widely in their staffing patterns, admission criteria, and outcomes (49) . The impact of postacute care facility type on PMV care deserves further attention.
The wide difference in cost-effectiveness ratios we found based on age and predicted mortality emphasizes the potential importance of prognostic models for survival, quality of life, and functional status for this population. Access to prognostic data does not change clinicians' practice in certain situations, but more confident knowledge of prognosis may improve the quality of patient-clinician and family-clinician communication in the ICU setting (50, 51) . Skilled communication about quality of life, survival, and caregiving needs also may prepare families for expected needs, ensure a patient's wishes are followed appropriately, reduce time spent in the ICU before death, and increase family satisfaction (52) (53) (54) .
Comparison with Other Literature. This is the first extensive economic anal- ysis of PMV to our knowledge, although our findings both complement and extend previous economic research pertaining to the critically ill. Dr. Cohen and colleagues (55) (56) found that severely ill persons from 65 to 74 yrs old who had a Ͼ50% risk of death at 2 months had lifetime incremental costs exceeding $132,000 in 2005 dollars per QALY gained by providing ventilation compared with withholding ventilationsomewhat higher than the $101,787 per QALY it cost high-risk PMV patients in our analysis. In contrast to these authors, we observed lower age-based survival and higher costs per QALY with advancing age. However, Dr. Heyland and colleagues (16) found that treating general ICU patients for Ͼ14 days cost only $5,300 in 2005 dollars per life-year saved compared with withdrawal of care, although this assumed a 15-yr survival and a comparatively low severity of illness.
The cost-effectiveness ratios associated with PMV provision are much higher than other medical therapies accepted as cost effective among the critically ill, such as the $27,400 per QALY gained by provision of drotrecogin alpha to persons with severe sepsis or the cost savings of antiseptic-impregnated central venous catheters (33, 57) . PMV's value is significantly less than many therapies for the noncritically ill elderly, including the use of statins after myocardial infarction ($18,100 per QALY) or influenza vaccination (58, 59) . Some may feel that a standard cost-effectiveness benchmark of $50,000 per QALY is inappropriately low for the critically ill population, but many societal members nonetheless may view as excessive the outlay of $162,000 per QALY for PMV provision to high-risk 80yr-olds (13) .
Limitations. Our analyses have important limitations. First, we used a number of different sources of data, which could introduce systemic bias. However, we used what we felt to be the best estimates available from the medical literature, explored the range of data inputs in sensitivity analyses, and still found our results to be relatively robust. Also, because the withdrawal of ventilation comparator was based on results of an observational study and not a randomized trial comparing ventilation strategies, the clinical characteristics of base-case and comparison patients are not perfectly matched. We believe, however, that this was the most clinically realistic way to estimate what patient costs and benefits would be if a course of PMV was not pursued. We did not include physician costs, because of difficulty standardizing acute and postacute care payments for these services. Given the similar inpatient costs and low postdischarge survival, the importance of this deficit is unlikely to change our primary findings that PMV incremental cost-effectiveness ratios are generally high. Also, because of the limitations of our data sources, we were unable to determine how specific disease states and detailed aspects of resource utilization affected costs and effects. Finally, we do not intend to dehumanize the clinicianpatient and clinician-family dynamic with our analyses, especially considering the importance that physicians place on interpreting patients' wishes in the setting of withdrawing life-sustaining therapies (60) . Nonetheless, we believe that a pragmatic societal perspective is most appropriate for economic analyses that have implications for maximizing resource distribution.
CONCLUSIONS
Our analyses show that PMV provision is associated with low cost effectiveness among the elderly and those with a low likelihood of 1-yr survival. Ideally, the development of PMV-specific prognostic models could facilitate communication of likely health outcomes and help maximize PMV value. Additional benefit could be realized by reducing costs of acute hospitalization with lower intensity units for stable patients and by minimizing postacute care complications, thereby reducing readmissions and increasing quality of life. graphic area, disproportionate share factors, and medical education provision. Lower and upper ranges in sensitivity analyses were based on DRG 541/542 costs without outlier correction ($111,194) and the 95th percentile of length of stay (70 days) and associated costs of $185,770. Costs for patients defined by the alternate PMV definition (ventilation Ն4 days with tracheostomy placement) also were based on DRG 541/ 542 without outlier correction ($111,194) . For short-term mechanical ventilation patients (Ն2 days but Ͻ7 days), costs ($45,818) were based on standard payments for DRG 475 (acute respiratory failure without tracheostomy placement) adjusted for outlier status derived from the cohort.
Inpatient hospitalization for withdrawal-of-ventilation patients: For patients from whom ventilation was withdrawn between ventilator days 7 and 21, the comparator group to both PMV groups, the payor's costs of $52,269 were calculated from the Pittsburgh cohort data as described above based on DRG 475 with adjustment for length-of-stay outlier status (7) . The withdrawal-ofventilation comparison group for the short-term ventilation group was assumed to receive the standard DRG 475 reimbursement of $21,575.
Hospital readmission costs:
Because most recent critical care recipients' readmissions are directly related to the original disease process, we assumed that readmission would cost $13,627 based on a diagnosis that a PMV recipient might commonly experience pneumonia (DRG 79) (26, 27, 31) . In sensitivity analyses, we chose a lower bound corresponding to the average floor admission paid by Medicare ($7,237) and an upper bound based on average costs ($26,699) derived from a recent study of prolonged ventilation patient readmissions (26, 32) . Patients who required intensive care were assumed to have a pneumonia that progressed to sepsis (DRG 416) and to have total hospital costs of $23,725 (31) . Cost ranges in sensitivity analyses included an upper bound corresponding to that seen for respiratory failure necessitating ventilation used for the comparator short-term ventilation group (DRG 475; $45,818) and a lower bound representing the average Medicare payment for ICU care ($14,515 after adjustment to 2005 dollars) (32).
Postacute Care Costs
We calculated LTAC costs ($71,641) by adjusting the 2005 standard federal prospective payment rate for LTACs by the Pittsburgh area wage index, the long-term care hospital relative weight for DRG 475, and the budget neutrality offset factor (34) . Skilled nursing facility costs were based on average Medicare payments for patients coded as DRG 483 during their acute hospitalization and adjusted for the case mix, functional status, and comorbidities (19) . The cost for an episode of long-term nursing home care ($45,152) was calculated by multiplying the average length of stay for long-term nursing home residents 65 yrs old and older (272 days) by the average per diem cost ($166) (21, 23, 35) . For those managed in a nursing facility with expertise in long-term ventilation care, we also assumed an average length of stay of 272 days but included per diem costs of $449 based on Medicaid data (35) . Medicare inpatient rehabilitation payments for patients ($27,197) were based on standard reimbursements weighted for case mix and geographic location (36) . Home healthcare payments ($2,851) were estimated for all persons discharged home from an acute care facility by adjusting the average base payment made for the first 60 days of care by Medicare for case mix (37) . Finally, we incorporated agespecific annual future expected health costs based on both Medicare and Blue Cross & Blue Shield data sets (38) .
